AQ-13 is a compound structurally similar to chloroquine, a widely used drug that is partly responsible for the decline of malaria in the last 50 years. When taken in large doses, chloroquine sometimes can cause headaches and blurry vision.
All symptoms cease when treatment ceases.
The irony is that while it has helped many malaria patients, its extensive use has resulted in the development of drug-resistant strains of malaria that does not respond well to chloroquine. If we are able to introduce a this new drug, we could significantly reinvigorate our fight against malaria. Men and women between the ages of 21 and 45 in good health can volunteer for the study. They do not need to have had malaria, nor can they catch malaria from AQ-13. Volunteers undergo a basic physical and heart monitor to ensure they are in healthy condition, and are not pregnant.